CL2015003333A1 - Vacunas de e1e2 del vhc y métodos de uso - Google Patents

Vacunas de e1e2 del vhc y métodos de uso

Info

Publication number
CL2015003333A1
CL2015003333A1 CL2015003333A CL2015003333A CL2015003333A1 CL 2015003333 A1 CL2015003333 A1 CL 2015003333A1 CL 2015003333 A CL2015003333 A CL 2015003333A CL 2015003333 A CL2015003333 A CL 2015003333A CL 2015003333 A1 CL2015003333 A1 CL 2015003333A1
Authority
CL
Chile
Prior art keywords
vhc
vaccines
methods
Prior art date
Application number
CL2015003333A
Other languages
English (en)
Spanish (es)
Inventor
Michael Houghton
Darren Hockman
John L Law
Michael Logan
Lorne D Tyrrell
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Publication of CL2015003333A1 publication Critical patent/CL2015003333A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2015003333A 2013-05-15 2015-11-13 Vacunas de e1e2 del vhc y métodos de uso CL2015003333A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361823712P 2013-05-15 2013-05-15
US201361887229P 2013-10-04 2013-10-04
PCT/IB2014/001972 WO2015132619A1 (en) 2013-05-15 2014-05-15 E1e2 hcv vaccines and methods of use

Publications (1)

Publication Number Publication Date
CL2015003333A1 true CL2015003333A1 (es) 2016-09-30

Family

ID=54054625

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003333A CL2015003333A1 (es) 2013-05-15 2015-11-13 Vacunas de e1e2 del vhc y métodos de uso

Country Status (8)

Country Link
US (3) US20210145963A9 (enExample)
EP (2) EP2996718B1 (enExample)
JP (5) JP2016520077A (enExample)
CN (2) CN105263517B (enExample)
AU (3) AU2014385320B2 (enExample)
CA (1) CA2909586C (enExample)
CL (1) CL2015003333A1 (enExample)
WO (1) WO2015132619A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117229414A (zh) * 2015-10-08 2023-12-15 艾伯塔大学理事会 丙型肝炎病毒e1/e2异二聚体及其生产方法
NZ751943A (en) * 2016-09-21 2025-08-29 Univ Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
AU2017341735B2 (en) 2016-10-11 2022-01-13 Helmholtz Center for Infection Research Hepatitis C virus immunogenic compositions comprising as an adjuvant a cyclic dinucleotide or an archaeosome and methods of use thereof
CN112601548A (zh) * 2018-03-16 2021-04-02 艾伯塔大学理事会 丙型肝炎病毒肽组合物及其使用方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
WO1994021292A1 (en) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
AU3241095A (en) 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AU4992197A (en) 1996-10-11 1998-05-11 Regents Of The University Of California, The Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69841015D1 (de) 1997-05-06 2009-09-10 Novartis Vaccines & Diagnostic Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
JP4101888B2 (ja) 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
AU746163B2 (en) 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
BRPI9915545B8 (pt) 1998-10-16 2021-05-25 Glaxosmithkline Biologicals Sa composição de vacina, processo para preparação da mesma e kit compreendendo dois recipientes.
DE60043930D1 (de) 1999-03-19 2010-04-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
DE60014076T2 (de) 1999-04-19 2005-10-13 Glaxosmithkline Biologicals S.A. Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
TR200200774T2 (tr) 1999-09-24 2002-08-21 Smithkline Beecham Biologicals S.A. Aşılar.
CZ20033515A3 (cs) * 2001-06-29 2005-01-12 Chiron Corporation Kompozice vakcíny HCV E1E2
US7348011B2 (en) * 2005-06-10 2008-03-25 Sudershan Biotech Ltd. Hepatitis C virus vaccine
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
US8603468B2 (en) * 2007-11-06 2013-12-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Neutralization of HCV
WO2014060851A2 (en) * 2012-10-05 2014-04-24 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof

Also Published As

Publication number Publication date
AU2020200216A1 (en) 2020-02-06
CA2909586A1 (en) 2015-09-11
JP2019142962A (ja) 2019-08-29
AU2022200747A1 (en) 2022-02-24
JP2016520077A (ja) 2016-07-11
EP2996718B1 (en) 2020-01-15
US20240316186A1 (en) 2024-09-26
CN112999344A (zh) 2021-06-22
AU2014385320B2 (en) 2019-10-10
US20210145963A9 (en) 2021-05-20
AU2014385320A1 (en) 2015-11-12
JP2024156917A (ja) 2024-11-06
CN105263517A (zh) 2016-01-20
HK1216395A1 (en) 2016-11-11
US20230098265A1 (en) 2023-03-30
JP2022172244A (ja) 2022-11-15
CA2909586C (en) 2021-08-31
EP2996718A4 (en) 2017-06-21
WO2015132619A1 (en) 2015-09-11
US20160067332A1 (en) 2016-03-10
EP3689375A1 (en) 2020-08-05
EP2996718A1 (en) 2016-03-23
JP2021059596A (ja) 2021-04-15
CN105263517B (zh) 2021-03-26

Similar Documents

Publication Publication Date Title
IL290547A (en) Antibodies and methods of use
IL280155A (en) Anti- SIGLEC-8 antibodies and methods of using them
CL2016001556A1 (es) Anticuerpos anti-cd3 y métodos de uso
CL2016001102A1 (es) Anticuerpos anti-claudina novedosos y métodos de uso.
IL251970B (en) Anti-cd79b antibodies and methods of use
CL2016000251A1 (es) Anticuerpos anti-activina y usos de los mismos
CL2016002462A1 (es) Anticuerpos anti-ox40 y métodos de uso
IL242394B (en) Cenicriviroc compositions and methods of making and using the same
HUE051982T2 (hu) Anti-alfa-szinuklein antitestek és alkalmazási eljárások
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
PL3623943T3 (pl) Urządzenie przenośne i sposób ograniczania korzystania z urządzenia przenośnego
CO7000747A2 (es) Anticuerpos anti-lrp5 y métodos de uso
SMT201600069B (it) Composizioni comprendenti 15-hepe e metodi d’uso delle stesse
IL244643A0 (en) Anti-ly6e antibodies and methods of use
HUE053033T2 (hu) Hidrolázoknak ellenálló kapszidokat alkalmazó készítmények és eljárások
EP2983661C0 (en) OXABICYCLOHEPTANE AND OXABICYCLOHEPTENE FORMULATIONS
CL2016000235A1 (es) Inhibidores de rorc2 y sus métodos de uso
CR20180296A (es) ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO
CO6940375A2 (es) Ensayo de lisiloxidasa-homólogo 2 y métodos de uso del mismo
EP2989432C0 (en) IMAGING APPARATUS AND METHOD
DK2969005T3 (da) Attenuerede influenzavira og -vacciner
BR112016004943A2 (pt) aparelho médico e uso
IL244354B (en) Influenza vaccine and therapy
DK2951208T3 (da) Anti-cd83 antistoffer og anvendelse deraf
CL2015002110A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna